To provide a novel class-A GPCR antagonist, a production method therefor, or a novel compound that interacts with a Na.sup.+-water cluster binding site of a class-A GPCR. Used is a compound or a salt thereof comprising a structure comprising a class-A GPCR-binding compound linked to a functional group that can bind to a Na.sup.+-water cluster binding site of the class-A GPCR. Also used is a method for producing a class-A GPCR antagonist, comprising the step of linking one compound with another compound that can bind to a Na.sup.+-water cluster binding site of the class-A GPCR.

Compositions capable of promoting mitofusin activation may include a mitofusin activator having a structure represented by ##STR00001##
any stereoisomer thereof, or any pharmaceutically acceptable salt thereof. G is N or CH, and A is an optionally substituted 5- or 6-membered cycloalkyl or heterocycloalkyl ring. X is (CH.sub.2).sub.3, OCH.sub.2CH.sub.2, CH.sub.2OCH.sub.2, CH.sub.2CH.sub.2O, Cyc, CH.sub.2Cyc, NR.sup.1 (CH.sub.2).sub.3, NR.sup.1OCH.sub.2CH.sub.2, NR.sup.1CH.sub.2OCH.sub.2, NR.sup.1CH.sub.2CH.sub.2O, or NR.sup.1Y, R.sup.1 is H or C.sub.1-C.sub.6 alkyl, and Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl, 1,3-cyclobutyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl, or 1,4-cyclohexyl. Z is (CH.sub.2).sub.n or (CH.sub.2).sub.n.sub.1 O(CH.sub.2).sub.n.sub.2. R.sup.2 is an optionally substituted aryl or heteroaryl group. Variable n is an integer ranging from 1 to 5, variable n.sub.1 is an integer ranging from 0 to 4, variable n.sub.2 is an integer ranging from 0 to 4, and n.sub.1+n.sub.2=n1.

The present invention is directed to a compound represented by Structural Formula (A):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

The present invention is directed to a compound represented by Structural Formula (A):

##STR00001##

or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.